These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

925 related articles for article (PubMed ID: 17671210)

  • 1. Proteasome function is required for DNA damage response and fanconi anemia pathway activation.
    Jacquemont C; Taniguchi T
    Cancer Res; 2007 Aug; 67(15):7395-405. PubMed ID: 17671210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphorylation of FANCD2 on two novel sites is required for mitomycin C resistance.
    Ho GP; Margossian S; Taniguchi T; D'Andrea AD
    Mol Cell Biol; 2006 Sep; 26(18):7005-15. PubMed ID: 16943440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FANCI phosphorylation functions as a molecular switch to turn on the Fanconi anemia pathway.
    Ishiai M; Kitao H; Smogorzewska A; Tomida J; Kinomura A; Uchida E; Saberi A; Kinoshita E; Kinoshita-Kikuta E; Koike T; Tashiro S; Elledge SJ; Takata M
    Nat Struct Mol Biol; 2008 Nov; 15(11):1138-46. PubMed ID: 18931676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Convergence of the fanconi anemia and ataxia telangiectasia signaling pathways.
    Taniguchi T; Garcia-Higuera I; Xu B; Andreassen PR; Gregory RC; Kim ST; Lane WS; Kastan MB; D'Andrea AD
    Cell; 2002 May; 109(4):459-72. PubMed ID: 12086603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An ATR- and BRCA1-mediated Fanconi anemia pathway is required for activating the G2/M checkpoint and DNA damage repair upon rereplication.
    Zhu W; Dutta A
    Mol Cell Biol; 2006 Jun; 26(12):4601-11. PubMed ID: 16738325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth of persistent foci of DNA damage checkpoint factors is essential for amplification of G1 checkpoint signaling.
    Yamauchi M; Oka Y; Yamamoto M; Niimura K; Uchida M; Kodama S; Watanabe M; Sekine I; Yamashita S; Suzuki K
    DNA Repair (Amst); 2008 Mar; 7(3):405-17. PubMed ID: 18248856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated.
    Kennedy RD; Chen CC; Stuckert P; Archila EM; De la Vega MA; Moreau LA; Shimamura A; D'Andrea AD
    J Clin Invest; 2007 May; 117(5):1440-9. PubMed ID: 17431503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coordinated action of the Fanconi anemia and ataxia telangiectasia pathways in response to oxidative damage.
    Castillo P; Bogliolo M; Surralles J
    DNA Repair (Amst); 2011 May; 10(5):518-25. PubMed ID: 21466974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ATR couples FANCD2 monoubiquitination to the DNA-damage response.
    Andreassen PR; D'Andrea AD; Taniguchi T
    Genes Dev; 2004 Aug; 18(16):1958-63. PubMed ID: 15314022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoketone analogs of curcumin, a new class of Fanconi anemia pathway inhibitors.
    Landais I; Hiddingh S; McCarroll M; Yang C; Sun A; Turker MS; Snyder JP; Hoatlin ME
    Mol Cancer; 2009 Dec; 8():133. PubMed ID: 20043851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of the Fanconi anemia/BRCA pathway and recombination repair in the cellular response to solar ultraviolet light.
    Dunn J; Potter M; Rees A; Rünger TM
    Cancer Res; 2006 Dec; 66(23):11140-7. PubMed ID: 17145857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRCA1-independent ubiquitination of FANCD2.
    Vandenberg CJ; Gergely F; Ong CY; Pace P; Mallery DL; Hiom K; Patel KJ
    Mol Cell; 2003 Jul; 12(1):247-54. PubMed ID: 12887909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRCA1, FANCD2 and Chk1 are potential molecular targets for the modulation of a radiation-induced DNA damage response in bystander cells.
    Burdak-Rothkamm S; Rothkamm K; McClelland K; Al Rashid ST; Prise KM
    Cancer Lett; 2015 Jan; 356(2 Pt B):454-61. PubMed ID: 25304378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fanconi anemia D2 protein confers chemoresistance in response to the anticancer agent, irofulven.
    Wang Y; Wiltshire T; Senft J; Wenger SL; Reed E; Wang W
    Mol Cancer Ther; 2006 Dec; 5(12):3153-61. PubMed ID: 17172419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteasome inhibitors block DNA repair and radiosensitize non-small cell lung cancer.
    Cron KR; Zhu K; Kushwaha DS; Hsieh G; Merzon D; Rameseder J; Chen CC; D'Andrea AD; Kozono D
    PLoS One; 2013; 8(9):e73710. PubMed ID: 24040035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Replication Protein A (RPA) deficiency activates the Fanconi anemia DNA repair pathway.
    Jang SW; Jung JK; Kim JM
    Cell Cycle; 2016 Sep; 15(17):2336-45. PubMed ID: 27398742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FANCD2 monoubiquitination and activation by hexavalent chromium [Cr(VI)] exposure: activation is not required for repair of Cr(VI)-induced DSBs.
    Vilcheck SK; Ceryak S; O'Brien TJ; Patierno SR
    Mutat Res; 2006 Nov; 610(1-2):21-30. PubMed ID: 16893675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chk1-mediated phosphorylation of FANCE is required for the Fanconi anemia/BRCA pathway.
    Wang X; Kennedy RD; Ray K; Stuckert P; Ellenberger T; D'Andrea AD
    Mol Cell Biol; 2007 Apr; 27(8):3098-108. PubMed ID: 17296736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ATM engages autodegradation of the E3 ubiquitin ligase COP1 after DNA damage.
    Dornan D; Shimizu H; Mah A; Dudhela T; Eby M; O'rourke K; Seshagiri S; Dixit VM
    Science; 2006 Aug; 313(5790):1122-6. PubMed ID: 16931761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of BRCA1 sensitizes cells to proteasome inhibitors.
    Gu Y; Bouwman P; Greco D; Saarela J; Yadav B; Jonkers J; Kuznetsov SG
    Cell Death Dis; 2014 Dec; 5(12):e1580. PubMed ID: 25522274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.